SCYNEXIS Reports Third Quarter 2020 Financial Results and Provides Company Update
November 06, 2020 08:45 ET
|
Scynexis
In October, SCYNEXIS submitted a New Drug Application (NDA) for ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) with expected approval in mid-2021. SCYNEXIS estimates that there are...
SCYNEXIS to Present Data Supporting the Efficacy of Ibrexafungerp Against Invasive Fungal Infections at IDWeek 2020
October 21, 2020 08:30 ET
|
Scynexis
JERSEY CITY, N.J., Oct. 21, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Announces Submission of New Drug Application to the U.S. Food and Drug Administration for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infection
October 14, 2020 08:30 ET
|
Scynexis
NDA submission is supported by positive data from two Phase 3 studies (VANISH Program) in women with vulvovaginal candidiasis (VVC)As a qualified infectious disease product (QIDP), ibrexafungerp is...
SCYNEXIS to Present Two Posters Highlighting Ibrexafungerp for the Treatment of Vaginal Yeast Infection at the 23rd Annual Premier Women's Healthcare Virtual Conference
October 12, 2020 08:30 ET
|
Scynexis
JERSEY CITY, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS to Participate in H.C. Wainwright Conference and Maxim’s Antifungal Webinar
September 10, 2020 08:38 ET
|
Scynexis
JERSEY CITY, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Announces Presentations at 2020 IDSOG Virtual Annual Meeting Highlighting Ibrexafungerp’s Potential for the Treatment of Vulvovaginal Candidiasis
August 13, 2020 08:00 ET
|
Scynexis
Two oral presentations by VVC experts on ibrexafungerp, one in-vitro activity study and one on VANISH-303 study SCYNEXIS to sponsor symposium: “Current Challenges and Advancements in the Treatment of...
SCYNEXIS Reports Second Quarter 2020 Financial Results and Provides Company Update
August 10, 2020 08:20 ET
|
Scynexis
In July, SCYNEXIS announced that it had successfully conducted pre-NDA meetings with the FDA regarding ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC) more commonly known as vaginal...
SCYNEXIS Reports Successful Completion of Pre-NDA Meetings with the FDA Regarding Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis
July 29, 2020 08:00 ET
|
Scynexis
Following recent productive meetings, the Company remains on track to submit a New Drug Application (NDA) for the treatment of Vulvovaginal Candidiasis (VVC), also known as Vaginal Yeast Infection, in...
SCYNEXIS Announces Four Posters Presented at ASM Microbe 2020 Highlighting the Potential Clinical Utility of Ibrexafungerp
July 22, 2020 08:00 ET
|
Scynexis
JERSEY CITY, N.J., July 22, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Announces One-for-Ten Reverse Stock Split
July 16, 2020 09:00 ET
|
Scynexis
JERSEY CITY, N.J., July 16, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ : SCYX) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of...